S
Sanifit
Develops treatments for cardiovascular diseases
About Sanifit
Sanifit is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular calcification, particularly in patients with end-stage kidney disease. Operating in the biopharmaceutical sector, Sanifit serves patients suffering from severe cardiovascular conditions linked to chronic kidney disease. The company's primary product, SNF472, is designed to inhibit the progression of cardiovascular calcification, a major cause of morbidity and mortality in these patients. Sanifit generates revenue through funding from international investors, including venture capital funds, corporate venture funds, and private investors. The company has raised over 130 million euros in equity to date. Sanifit operates out of Palma de Mallorca, Spain, and San Diego, USA, and actively participates in investor conferences to secure additional funding and partnerships.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Palma, Spain
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 62.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Dietary Supplements, Biotechnology, Cardiology and cardiovascular, Superfood, Spinout, Hospital, Biotech and Pharma, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2021 | $231M | $231M | Vifor Pharma | ↗ |
| SERIES DOther financing | Jun 2019 | $61M | $242M | Lundbeckfonden Ventures · Andera Partners · Ysios Capital · Forbion Capital Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Sanifit is 360 monthly website visits, down 81.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
HealthEquity
Series B and later9 investors entered at this stage
Forbion Capital Partners
Baxter Ventures
CaixaBank
Ysios Capital
Lundbeckfonden Ventures
Gilde Healthcare
Andera Partners
Columbus Venture Partners
Alta Life Sciences
Other known investors2 additional known investors
University of the Balearic Islands
Vifor Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sanifit on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sanifit’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.